{"entity":{"id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","aka":[],"tldr":"A phase 3 trial of 5-Aminolevulinic acid in ovarian cancer, run by NX Development Corp, now recruiting.","summary":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) is a phase 3 interventional study registered as NCT05804370 by NX Development Corp, with 170 participants planned, started 2024-05-30 and due to reach its primary completion in 2028-09. Interventions recorded: Gleolan. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05804370","url":"https://clinicaltrials.gov/study/NCT05804370"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["aminolevulinic-acid-gleolan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05804370","phase":"3","setting":"A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer","sponsor":"NX Development Corp","enrolled":170,"outcomes":[]},"route":"/trials/nct05804370/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/"}]}}